Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials
Highlights • Our aim is to study efficacy of PPV-23 against CAP other than other PPV valences. • PPV-23 can prevent all-cause pneumonia among immunocompetent adults. • It has greater efficacy against CAP among the targeted population. • It shows protective trends for pneumococcal pneumonia and morta...
Saved in:
Published in | Vaccine Vol. 34; no. 13; pp. 1496 - 1503 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
18.03.2016
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Highlights • Our aim is to study efficacy of PPV-23 against CAP other than other PPV valences. • PPV-23 can prevent all-cause pneumonia among immunocompetent adults. • It has greater efficacy against CAP among the targeted population. • It shows protective trends for pneumococcal pneumonia and mortality from pneumonia. • It does not prevent all-cause mortality. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-4 content type line 23 ObjectType-Undefined-3 |
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2016.02.023 |